Tilling the Soil in Tanzania: What Do Emerging Economies Have to Offer?

Close to 70% of Tanzanian farmers are small scale resource-poor subsistence operators, cultivating an average of less than 1 to 3 hectares of mainly rain-fed land, deteriorated by continuous cropping and lack of fertility management. In the farmers’ effort to move up the commercialisation continuum and alleviate poverty through increased output and incomes, innovation and technical change is key. However, liquidity constraints and prohibitive prices have in the past discouraged farmer investment in capital goods (power tillers and tractors). This is a limiting factor for increased cropping area and timeliness of operation which has the potential to positively affect crop output and incomes. In the face of these difficulties, the farmer is prepared to trade-off quality and variety, for relatively low priced capital goods, provided they are good enough and rely less on heavily built infrastructure. In recent decades, the capital goods market for power tillers and tractors has become dynamic with respect to cost, quality and origin of production. With new entrants like China, India and Pakistan joining Western Europe, USA and Japan in the supply of farm machinery, the range of choice for the Tanzanian farmer is increasing. Chinese, Indian and Pakistani power tillers and tractors have some distinctiveness in their engineering, acquisition cost, operational cost and their supply chains which may be useful in more ways to the small farmer in Tanzania. This thesis appraises the pro-poor nature of emerging economy tillage capital goods, placing particular emphases on how an optimal technological choice is made. It examines the role that cost innovators’ from emerging economies (China/India/Pakistan) are playing in meeting the farmers’ choice objective particularly with regard to cost, labour intensity and scale of operation. In as far as Tanzanian farmers are concerned the study discusses the role that local institutions can play to enhance choice, access and efficient use of such capital goods for higher productivity which may translate into increased incomes. The study draws on both qualitative and quantitative data to compare advanced country tractors and power tillers with those from emerging economies and finds that; First, aid/government support, trade and FDI/licencing are key conduits for technology imports into Tanzania. However, trade has been very important for emerging economy machines whilst aid/government support has been found to be key for advanced country machines. Second, in terms of penetration and extent of use among Tanzanian farmers emerging economy machines are more popular than advanced country ones when it comes to power tillers. Nevertheless, the total stock of advanced country tractors in Tanzania are known to be larger than emerging economy ones; though we are recently witnessing a recent rapid increase in the former than the latter. Third, advanced country machines are generally superior in terms of engineering performance and work efficiency when compared with emerging economy ones. That said, it is worth noting that the advanced country machines are capital intensive and involve higher maintenance costs because of higher spare parts and repair cost. Finally, emerging economy machines are more pro-poor than matured market ones since they create more opportunities for employment and capability building among capital constrained users and dealers

Youth and Saving in Ghana: A Baseline Report From the YouthSave Ghana Experiment

Youth and Saving in Ghana: A Baseline Report From the YouthSave Ghana Experimen

What makes people happy with their lives in developing countries? Evidence from large-scale longitudinal data on Ghana

A key objective of development thought is to improve the welfare of people and enhance their satisfaction with life. This is important following literature that suggests that increasing incomes may not necessarily lead to happiness in the long term. In this regard, this study investigates the drivers of happiness in Ghana and the determinants of transitions into different happiness states. Using a nationwide panel dataset over three time periods and employing econometric techniques, the study found that among the key determinants of happiness in Ghana are assets, social capital/networks, health status, ethnicity, age and location of residence. The study further found that assets neutralize the effects of other vital drivers while social network has a moderating effect on how assets predict happiness. In contrast, an inverted U-shape was found for the importance of assets to happiness over one’s age, suggesting that assets begin to matter less for one’s happiness beyond a certain age threshold. Aside from assets and social network, which predict transitions from any state of happiness to the other, the importance of other correlates of the transitions largely varies by the initial state of happiness. The implications are discussed within the framework of the goals of development policy.Open access funding provided by University of Pretoria.http://link.springer.com/journal/11482hj2024Future AfricaSDG-03:Good heatlh and well-bein

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

BACKGROUND: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. METHODS: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). FINDINGS: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29-146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0- 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25-1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39-1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65-1·60]; p=0·92). INTERPRETATION: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention. FUNDING: British Heart Foundation

Indigenous risk management practices and their effects on small agribusiness firm growth amid economic crisis in Ghana

This paper estimates the effect of indigenous risk management practices (used by entrepreneurs) on small firm growth amid the current economic crisis in Ghana. The paper hypothesizes that indigenous risk management practices positively affect the growth of informal micro and small agri-food processing firms during the current economic crisis in Ghana. Cross–sectional and limited panel data (covering four years – from the end of 2019 to the end of 2022) have been used in the analysis. Firm Growth has been estimated using sales volume and the number of employees. Findings indicate that apart from savings for business purposes as an indigenous risk management strategy, diversification of economic activities, subscription to formal insurance, forward contracting, cooperative marketing, borrowing, sale of assets, and temporary wage employment outside the business exert a positive influence on small firm growth in terms of sales. Subscription to formal insurance and temporary wages outside the entrepreneur's business positively influence firm growth as related to growth in employee size. We recommend that policymakers design and implement policies that initiate and facilitate the development of marketing cooperatives to negotiate fair prices. This essential tool can help mitigate marketing risks to the agri-food processing entrepreneur. The police should facilitate rolling out skills development programs to increase entrepreneurs' capacities in forward contracting arrangements. Again, entrepreneurs of agri-food processing firms in the wider Ghanaian population should be educated on the need to subscribe to formal insurance to insulate them in times of property loss or personal accidents

Governance and Conservation Effectiveness in Protected Areas and Indigenous and Locally Managed Areas

Unidad de excelencia María de Maeztu CEX2019-000940-MIncreased conservation action to protect more habitat and species is fueling a vigorous debate about the relative effectiveness of different sorts of protected areas. Here we review the literature that compares the effectiveness of protected areas managed by states and areas managed by Indigenous peoples and/or local communities. We argue that these can be hard comparisons to make. Robust comparative case studies are rare, and the epistemic communities producing them are fractured by language, discipline, and geography. Furthermore the distinction between these different forms of protection on the ground can be blurred. We also have to be careful about the value of this sort of comparison as the consequences of different forms of conservation for people and nonhuman nature are messy and diverse. Measures of effectiveness, moreover, focus on specific dimensions of conservation performance, which can omit other important dimensions. With these caveats, we report on findings observed by multiple study groups focusing on different regions and issues whose reports have been compiled into this article. There is a tendency in the data for community-based or co-managed governance arrangements to produce beneficial outcomes for people and nature. These arrangements are often accompanied by struggles between rural groups and powerful states. Findings are highly context specific and global generalizations have limited value